<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-166504" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Peripheral Hypertrophic Subepithelial Corneal Degeneration</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moin</surname>
            <given-names>Kayvon A.</given-names>
          </name>
          <aff>American University of the Caribbean School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ronquillo</surname>
            <given-names>Yasmyne</given-names>
          </name>
          <aff>Hoopes Vision Research Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kayvon Moin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmyne Ronquillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-166504.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Peripheral hypertrophic subepithelial corneal degeneration (PHSCD) was first described by Maust&#x000a0;and Raber in 2003, who reported 6 patients with peripheral, symmetric, and bilateral subepithelial fibrotic lesions in the periphery and mid-periphery of the cornea. The authors explained that although similar to Salzmann nodular degeneration, these 6 women had ocular irritation symptoms and no preceding episodes of keratitis or inflammation.<xref ref-type="bibr" rid="article-166504.r1">[1]</xref>&#x000a0;Since its initial description, several cases have been reported describing PHSCD as an isolated diagnosis.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref><xref ref-type="bibr" rid="article-166504.r3">[3]</xref><xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r5">[5]</xref><xref ref-type="bibr" rid="article-166504.r6">[6]</xref><xref ref-type="bibr" rid="article-166504.r7">[7]</xref>&#x000a0;Many of these cases have reported risk factors, various clinical presentations, diagnostic findings, and management strategies&#x000a0;for patients with PHSCD.&#x000a0;</p>
        <p>PHSCD is currently understood to be a relatively rare, benign ocular condition characterized by subepithelial fibrous tissue growth in the peripheral cornea. PHSCD often presents as an asymptomatic condition but can occasionally cause discomfort or visual disturbances depending on the extent and location of the degeneration. This degeneration is distinct from other corneal dystrophies and degenerations due to its specific peripheral location and the nature of the subepithelial deposits found between the epithelium and the Bowman layer.<xref ref-type="bibr" rid="article-166504.r8">[8]</xref> These deposits are composed mainly of fibrous tissue and can lead to a whitish, opaque appearance at the affected sites; the subepithelial layer&#x000a0;is crucial for maintaining corneal transparency and overall ocular health.&#x000a0;However, extensive peripheral involvement can sometimes encroach upon the central cornea, potentially affecting vision.<xref ref-type="bibr" rid="article-166504.r9">[9]</xref></p>
        <p>Patients with PHSCD often present with ocular irritation or dry eye symptoms such as redness, tearing, or a foreign body sensation. Asymptomatic presentations are well-documented; in these cases, PHSCD is an incidental finding.<xref ref-type="bibr" rid="article-166504.r3">[3]</xref>&#x000a0;The diagnosis of PHSCD is primarily clinical, based on the characteristic appearance of the cornea during slit-lamp examination.<xref ref-type="bibr" rid="article-166504.r10">[10]</xref>&#x000a0;The natural course of PHSCD varies among individuals. In some cases, the condition may stabilize without significant progression, whereas in others, the fibrous tissue proliferation may continue gradually over time.&#x000a0;</p>
        <p>Management of PHSCD focuses on alleviating symptoms, addressing visual impairment, and preventing further progression. Treatment options include&#x000a0;lubricating eye drops to reduce discomfort and irritation and anti-inflammatory medications to manage underlying ocular surface inflammation. In severe cases, surgical removal of the fibrous tissue may be considered, although this is rarely necessary. Surgical management includes manual superficial keratectomy or phototherapeutic keratectomy.<xref ref-type="bibr" rid="article-166504.r11">[11]</xref>&#x000a0;Regular follow-up with an ophthalmologist is essential for monitoring the condition and adjusting the management plan. Understanding&#x000a0;the anatomy, natural history, and patterns of spread of PHSCD is crucial for effective diagnosis and management. Regular ophthalmic evaluations are essential for ensuring timely intervention and preserving ocular health.<xref ref-type="bibr" rid="article-166504.r12">[12]</xref></p>
      </sec>
      <sec id="article-166504.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The current etiology of PHSCD is largely unknown.&#x000a0;Some reports suggest that PHSCD may occur after chronic ocular surface diseases such as dry eye disease, contact lens&#x000a0;wear, or ocular surgery.<xref ref-type="bibr" rid="article-166504.r6">[6]</xref>&#x000a0;Others&#x000a0;argue that PHSCD might be a primary disease.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref>&#x000a0;A study reported that a case of PHSCD occurred soon after the patient underwent femtosecond-assisted laser-assisted in situ keratomileusis (LASIK), with resolution after superficial keratectomy.<xref ref-type="bibr" rid="article-166504.r6">[6]</xref>&#x000a0;Another&#x000a0;study suggested that the human leukocyte antigen-B*44 allele and the 8.1 ancestral haplotype may be immunological factors that predispose patients to develop PHSCD, but the same authors reported a subsequent study's conclusions refuted this claim.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r13">[13]</xref></p>
        <p>PHSCD has been hypothesized to be associated with decreased tear film production and reduced tear film stability.<xref ref-type="bibr" rid="article-166504.r14">[14]</xref> Study observations&#x000a0;have&#x000a0;shown decreased Schirmer test results (see <bold>Image. </bold>Schirmer Test Results)&#x000a0;and tear break-up time scores in patients with PHSCD.<xref ref-type="bibr" rid="article-166504.r15">[15]</xref>&#x000a0;The Schirmer test quantifies the number of tears an eye produces, whereas the tear break-up time measures the time it takes for a dry spot to form on the cornea under fluorescein staining&#x000a0;using the slit lamp.</p>
        <p>The primary causes of PHSCD are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic ocular surface inflammation, such as blepharitis, dry eye syndrome, and allergic conjunctivitis <xref ref-type="bibr" rid="article-166504.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Ocular trauma caused by mechanical force, chemical exposure, or surgical procedures&#x000a0;<xref ref-type="bibr" rid="article-166504.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Age-related changes</p>
          </list-item>
          <list-item>
            <p>Genetic predisposition</p>
          </list-item>
          <list-item>
            <p>Environmental factors, such as ultraviolet radiation, pollutants, and allergens</p>
          </list-item>
          <list-item>
            <p>Systemic conditions (for example, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus)</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiencies, such as vitamins A and C</p>
          </list-item>
          <list-item>
            <p>Chronic infections&#x000a0;<xref ref-type="bibr" rid="article-166504.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Previous ocular surgeries, such as pterygium excision and cataract surgery <xref ref-type="bibr" rid="article-166504.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Contact lens wear&#x000a0;<xref ref-type="bibr" rid="article-166504.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Tear film abnormalities</p>
          </list-item>
          <list-item>
            <p>Exposure to toxic substances</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PHSCD typically occurs bilaterally and symmetrically, as&#x000a0;observed in 81.6% of documented cases, and predominantly affects middle-aged women in White populations, with a woman-to-man ratio of 4:1.<xref ref-type="bibr" rid="article-166504.r1">[1]</xref><xref ref-type="bibr" rid="article-166504.r13">[13]</xref>&#x000a0;The overall incidence rate of this condition is unknown due to the scarcity of reported cases.&#x000a0;Regular ophthalmic evaluations and advanced imaging techniques help identify and manage PHSCD, providing better insights into its epidemiological patterns.<xref ref-type="bibr" rid="article-166504.r6">[6]</xref></p>
        <p>Age groups:&#x000a0;PHSCD&#x000a0;is predominantly observed in older adults, typically those older than 50. Cases in younger individuals are rare but possible.<xref ref-type="bibr" rid="article-166504.r14">[14]</xref></p>
        <p>Geographical distribution:<bold>&#x000a0;</bold>Data on the specific prevalence of PHSCD in the&#x000a0;United States are limited, but it is recognized among the&#x000a0;older population during routine ophthalmic examinations. Similar to the distribution in the United States, PHSCD is observed in older adults globally, with no specific regions showing higher prevalence rates. The condition is likely underreported due to its often asymptomatic nature.<xref ref-type="bibr" rid="article-166504.r14">[14]</xref></p>
        <p>General prevalence:&#x000a0;The overall prevalence of PHSCD is considered low compared to other corneal degenerations. Due to its asymptomatic presentation in many cases, the condition might be more common than reported.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref></p>
        <p>Risk factors:<bold>&#x000a0;</bold>Increased age, chronic ocular surface inflammation, history of ocular trauma, and previous ocular surgeries are significant risk factors.</p>
      </sec>
      <sec id="article-166504.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiological mechanisms of PHSCD are not yet understood but are believed to involve degeneration processes similar to those observed in Salzmann nodular degeneration.<xref ref-type="bibr" rid="article-166504.r5">[5]</xref> Salzmann nodular degeneration and PHSCD are&#x000a0;believed to occur due to the enzymatic destruction of the epithelial basement membrane&#x000a0;through increased levels of matrix metalloproteinase-2, resulting in secondary deposition of extracellular matrix components&#x000a0;and a fragmented or absent Bowman layer.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r21">[21]</xref><xref ref-type="bibr" rid="article-166504.r22">[22]</xref>&#x000a0;</p>
        <p>However, PHSCD tends to have larger and more&#x000a0;circumferential&#x000a0;corneal opacities compared to Salzmann nodular degeneration and typically has no presence of inflammation or preceding episodes of keratitis.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref>&#x000a0;The fibrosis in PHSCD may extend to the mid-periphery but always spares the central cornea. The current literature has not described any systemic diseases or conditions definitively associated with PHSCD.</p>
      </sec>
      <sec id="article-166504.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological findings of tissue samples from patients with PHSCD may include corneal epithelial thinning with a discontinuous, fragmented, or porous basement membrane and fibrosis between the epithelium and an absent or degenerated Bowman layer positive for vimentin staining. Acute or chronic inflammation&#x000a0;may be absent in observed specimens.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref></p>
        <p>Key histopathological characteristics of PHSCD include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Subepithelial fibrosis: The primary histopathological feature of PHSCD is the presence of fibrous tissue beneath the corneal epithelium. This fibrous tissue is composed of collagen fibers and fibroblasts responsible for the proliferation and deposition of the fibrous material.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Disorganization of collagen fibers: The collagen fibers in the subepithelial region are disorganized, leading to the characteristic whitish opacity observed clinically.<xref ref-type="bibr" rid="article-166504.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infiltration of inflammatory cells: Chronic inflammation is often associated with PHSCD. Histopathological slides may show infiltration of inflammatory cells, such as lymphocytes and macrophages, in the cornea's subepithelial and superficial stromal layers.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thickening of the basement membrane: The basement membrane, which separates the epithelium from the underlying stroma, may be thickened, contributing to the irregularities observed on the corneal surface.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Absence of vascularization: Unlike other forms of corneal degeneration that may involve neovascularization, PHSCD typically does not show new blood vessel formation within the fibrotic areas.<xref ref-type="bibr" rid="article-166504.r24">[24]</xref><xref ref-type="bibr" rid="article-166504.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Obtaining a comprehensive medical history and performing a thorough physical examination are critical when evaluating patients with suspected PHSCD.</p>
        <p>
<bold>History</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient demographics: PHSCD typically affects older adults, with the most common cases occurring in those 50 or older.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms: Patients with PHSCD typically present with bilateral decreased visual acuity due to astigmatism, a mild itching&#x000a0;or burning sensation, a foreign body sensation, or a conjunctival injection. Some patients may also be asymptomatic.<xref ref-type="bibr" rid="article-166504.r1">[1]</xref><xref ref-type="bibr" rid="article-166504.r3">[3]</xref>&#x000a0;Blurred vision can occur if the central cornea is involved.<xref ref-type="bibr" rid="article-166504.r26">[26]</xref><xref ref-type="bibr" rid="article-166504.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Previous ocular conditions: A history of chronic ocular surface inflammation, such as blepharitis or dry eye syndrome, prior ocular trauma or surgeries, such as cataract surgery or pterygium excision, and exposure to environmental irritants may be present.<xref ref-type="bibr" rid="article-166504.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Systemic conditions: Patients may or may not have a history of systemic autoimmune diseases or nutritional deficiencies such as vitamin A or C deficiencies.<xref ref-type="bibr" rid="article-166504.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination Findings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Slit-lamp examination findings may include:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Bilateral, symmetric, whitish, or opaque subepithelial deposits, primarily in the peripheral cornea, forming a ring-like pattern in the periphery may be observed.</p>
              </list-item>
              <list-item>
                <p>The central cornea is typically clear, but extensive peripheral involvement can encroach upon the central area.</p>
              </list-item>
              <list-item>
                <p>Superficial neovascularization may also be observed at the base of the fibrosis.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r10">[10]</xref></p>
              </list-item>
              <list-item>
                <p>Linear iron deposits may also be observed along the central edge of the opacification.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inflammation: Signs of chronic inflammation may be present in the conjunctiva or eyelids.<xref ref-type="bibr" rid="article-166504.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Corneal surface: The affected areas may show irregularities in the corneal surface due to subepithelial fibrous tissue proliferation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visual acuity is typically&#x000a0;preserved if the central cornea remains unaffected but can be reduced if fibrous tissue extends centrally.</p>
          </list-item>
          <list-item>
            <p>Light sensitivity: Some patients may report increased sensitivity to light (photophobia).<xref ref-type="bibr" rid="article-166504.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>PHSCD is a relatively rare corneal disorder that necessitates a comprehensive evaluation. Evaluating patients with PHSCD requires a multifaceted approach involving detailed clinical examinations, laboratory tests, specialized imaging techniques, and adherence to national and international guidelines. Following guidelines from organizations such as the American Academy of Ophthalmology (AAO), European Society of Cataract and Refractive Surgeons (ESCRS), International Council of Ophthalmology (ICO), and National Institutes of Health (NIH) ensures a comprehensive and standardized approach to diagnosing and treating patients with&#x000a0;PHSCD.</p>
        <p>
<bold>Clinical Examination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Manifest refraction: The first step in evaluating PHSCD is manifest refraction to quantify the patient's refractive error and cylindrical astigmatism. Manifest refraction may show a cylindrical astigmatism of 2.0 diopters or more.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Slit-lamp examination:<bold>&#x000a0;</bold>Slit-lamp biomicroscopy should be used to assess the clinical signs of PHSCD and rule out other diagnoses. Findings may include peripheral and circumferential subepithelial fibrosis in both eyes, associated neovascularization or pannus, and linear iron deposits along the central edge of the areas of opacification.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Visual acuity test: This test helps determine the extent of visual impairment caused by the corneal changes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Specular microscopy: This technique evaluates the health of the corneal endothelium, which can be affected by chronic corneal conditions such as PHSCD.</p>
          </list-item>
        </list>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tear film analysis:&#x000a0;This evaluation includes tests such as tear break-up time, Schirmer test, and ocular surface staining to assess the quality and quantity of the tear film. Chronic ocular surface diseases can often coexist with tear film abnormalities.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Corneal sensitivity test: Measuring corneal sensitivity can help determine the extent of corneal nerve involvement that can be affected in degenerative conditions.<xref ref-type="bibr" rid="article-166504.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Radiographic and Other Imaging&#x000a0;Techniques</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Corneal topography: This imaging technique maps corneal curvature,&#x000a0;revealing any irregularities or elevations due to hypertrophic changes. Corneal topography may demonstrate flattening or thickening of the cornea at areas of fibrosis.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref>&#x000a0;Assessing the corneal surface's shape is crucial for&#x000a0;planning interventions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anterior segment optical coherence tomography:&#x000a0;Providing detailed images of the corneal structure is particularly useful in assessing the depth and extent of subepithelial deposits. Anterior segment optical coherence tomography (AS-OCT) may show continuous, homogenous, well-demarcated hyperreflective subepithelial bands associated with hyperreflectivity in the anterior stroma.<xref ref-type="bibr" rid="article-166504.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In vivo confocal microscopy: This imaging modality allows in vivo visualization of the corneal layers at a cellular level, helping distinguish PHSCD from other corneal dystrophies or degenerations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ultrasound biomicroscopy: This imaging procedure<bold>&#x000a0;</bold>is helpful in cases where AS-OCT is inconclusive. Ultrasound biomicroscopy provides&#x000a0;high-resolution images of the anterior segment.<xref ref-type="bibr" rid="article-166504.r29">[29]</xref></p>
          </list-item>
        </list>
        <p><bold>Biopsy</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>A biopsy of the affected perilimbal areas may be considered to rule out conjunctival intraepithelial neoplasia.<xref ref-type="bibr" rid="article-166504.r15">[15]</xref><xref ref-type="bibr" rid="article-166504.r30">[30]</xref><xref ref-type="bibr" rid="article-166504.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>
<bold>National and International Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>American Academy of Ophthalmology: The AAO provides guidelines for the diagnosis and management of corneal degenerations and dystrophies, including the use of slit-lamp biomicroscopy, corneal topography, and AS-OCT as standard evaluation tools.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>European Society of Cataract and Refractive Surgeons: The ESCRS recommends comprehensive corneal imaging and regular monitoring for progressive degenerative conditions such as PHSCD. The organization also emphasizes the importance of OCT and in vivo confocal microscopy in the diagnostic process.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>International Council of Ophthalmology: The ICO provides a framework for diagnosing and managing corneal conditions, recommending the use of advanced imaging techniques and standardized visual acuity assessments in evaluating patients with corneal degenerations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>National Institutes of Health: The NIH suggests including genetic testing where applicable, particularly if PHSCD is suspected to have a hereditary component. Participation in clinical trials and registries for rare corneal diseases is encouraged to improve understanding and management strategies.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treating and managing PHSCD requires a multifaceted approach comprising medical and surgical interventions. The individual management strategy is tailored to the severity of the condition and the patient's symptoms. Management also depends on the patient's visual acuity; asymptomatic patients with unaffected vision do not require any intervention.</p>
        <p>Patients with unaffected visual acuity and mild ocular irritation or dry eye symptoms associated with PHSCD can be instructed to use preservative-free artificial tears or other lubricating eye drops as needed. If symptoms are unresponsive to over-the-counter dry eye medications, prescription eye drops such as loteprednol 0.25%, lifitegrast&#x000a0;0.50%, or cyclosporine 0.05% may be considered.<xref ref-type="bibr" rid="article-166504.r32">[32]</xref>&#x000a0;Results from a study demonstrated that&#x000a0;approximately&#x000a0;30% of patients with PHSCD were successfully treated with conservative therapy alone.<xref ref-type="bibr" rid="article-166504.r30">[30]</xref></p>
        <p>A combination of medical and surgical approaches can be tailored to the patient's individual needs. Lubricating eye drops, anti-inflammatory medications, and hypertonic saline are common medical treatments, whereas surgical options include superficial keratectomy, phototherapeutic keratectomy, and corneal transplantation. Other interventions, such as punctal&#x000a0;plugs and amniotic membrane transplantation, may also be used.&#x000a0;Adhering to guidelines from organizations such as the AAO, ESCRS, ICO, and NIH ensures that patients receive evidence-based and up-to-date treatment.</p>
        <p>
<bold>Medical Interventions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lubricating eye drops: Artificial tears are often the first line of treatment to alleviate dry eye discomfort and improve tear film stability.</p>
          </list-item>
          <list-item>
            <p>Anti-inflammatory medications: Topical corticosteroids or nonsteroidal anti-inflammatory drugs may be prescribed to reduce inflammation and corneal edema.</p>
          </list-item>
          <list-item>
            <p>Hypertonic saline drops or ointments: These agents<bold>&#x000a0;</bold>reduce corneal edema by drawing out excess fluid from the cornea.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bandage contact lenses: Soft contact lenses can protect the corneal surface, provide comfort, and promote the healing of epithelial defects.</p>
          </list-item>
        </list>
        <p>
<bold>Additional&#x000a0;Interventions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Punctal plugs: These&#x000a0;plugs are inserted into the tear ducts to retain moisture on the ocular surface, thereby alleviating dry eye symptoms.</p>
          </list-item>
          <list-item>
            <p>Amniotic membrane transplantation: This procedure can be used in cases with persistent epithelial defects or severe ocular surface disease. The amniotic membrane promotes healing and reduces inflammation.</p>
          </list-item>
          <list-item>
            <p>Intense pulsed light therapy: This therapy can benefit patients with associated meibomian gland dysfunction, improving tear film stability and reducing evaporative dry eye symptoms.<xref ref-type="bibr" rid="article-166504.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Surgical Management</bold>
</p>
        <p>Surgical management is reserved for patients with PHSCD who experience a decline in visual acuity secondary&#x000a0;to fibrotic encroachment of the visual axis. Keratectomy&#x000a0;has been shown to effectively and safely remove areas of fibrosis. Manual superficial keratectomy or phototherapeutic keratectomy&#x000a0;with an excimer laser may be considered.<xref ref-type="bibr" rid="article-166504.r11">[11]</xref>&#x000a0;The epithelium of the affected area should be first scraped off.<xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r30">[30]</xref>&#x000a0;The fibrous tissue can be removed manually using&#x000a0;Colibri forceps, a Beaver, a crescent blade, or excimer laser ablation.<xref ref-type="bibr" rid="article-166504.r13">[13]</xref>&#x000a0;Topical mitomycin C 0.4 mg/mL drops may be applied for 20 seconds after excision to minimize recurrence rates and postoperative haze formation.<xref ref-type="bibr" rid="article-166504.r30">[30]</xref><xref ref-type="bibr" rid="article-166504.r33">[33]</xref>&#x000a0;Postoperative management should include using bandage contact lenses for 5 to 7 days, topical nonsteroidal anti-inflammatory eye drops, and artificial tears. Oral nonsteroidal anti-inflammatory medications may also be considered.<xref ref-type="bibr" rid="article-166504.r30">[30]</xref>&#x000a0;In advanced cases with significant visual impairment or structural damage, a partial or full-thickness corneal transplant (penetrating keratoplasty) may be necessary.</p>
        <p>
<bold>National and International Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>American Academy of Ophthalmology
<list list-type="bullet"><list-item><p>Preferred practice pattern: The AAO recommends a stepwise approach, starting with conservative medical management and progressing to surgical interventions if necessary. This organization emphasizes regular monitoring&#x000a0;using&#x000a0;imaging techniques for assessment.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>European Society of Cataract and Refractive Surgeons
<list list-type="bullet"><list-item><p>Guidelines on corneal surgery: The ESCRS guidelines suggest using phototherapeutic keratectomy for superficial corneal irregularities and recommend keratoplasty in cases of significant corneal scarring or thinning.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>International Council of Ophthalmology
<list list-type="bullet"><list-item><p>Management of corneal degenerations: The ICO advocates for individualized treatment plans based on the severity of the condition and patient-specific factors. This organization highlights the importance of integrating new technologies and treatments as they emerge.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>National Institutes of Health&#x000a0;
<list list-type="bullet"><list-item><p>Research and clinical trials: The NIH encourages participation in clinical trials to advance the understanding and treatment of rare corneal conditions such as PHSCD and supports the development of novel therapies and interventions.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating a patient with corneal fibrosis and neovascularization, the&#x000a0;differential diagnosis should include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent inflammatory disease&#x000a0;<xref ref-type="bibr" rid="article-166504.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Pterygium&#x000a0;<xref ref-type="bibr" rid="article-166504.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Pseudopterygium</p>
          </list-item>
          <list-item>
            <p>Conjunctival intraepithelial neoplasia&#x000a0;<xref ref-type="bibr" rid="article-166504.r4">[4]</xref><xref ref-type="bibr" rid="article-166504.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Salzmann nodular degeneration</p>
          </list-item>
          <list-item>
            <p>Band keratopathy</p>
          </list-item>
          <list-item>
            <p>Terrien marginal degeneration</p>
          </list-item>
          <list-item>
            <p>Peripheral ulcerative keratitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Marginal keratitis</p>
          </list-item>
          <list-item>
            <p>Lattice corneal dystrophy</p>
          </list-item>
          <list-item>
            <p>Fuchs endothelial dystrophy</p>
          </list-item>
          <list-item>
            <p>Keratoconus</p>
          </list-item>
          <list-item>
            <p>Epithelial basement membrane dystrophy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mooren ulcer</p>
          </list-item>
          <list-item>
            <p>Dellen</p>
          </list-item>
          <list-item>
            <p>Sclerokeratitis</p>
          </list-item>
          <list-item>
            <p>Phlyctenulosis</p>
          </list-item>
          <list-item>
            <p>Thygeson superficial punctate keratitis</p>
          </list-item>
          <list-item>
            <p>Herpes simplex keratitis</p>
          </list-item>
          <list-item>
            <p>Herpes zoster ophthalmicus</p>
          </list-item>
          <list-item>
            <p>Recurrent corneal erosion</p>
          </list-item>
          <list-item>
            <p>Posterior polymorphous corneal dystrophy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Granular corneal dystrophy</p>
          </list-item>
          <list-item>
            <p>Meesmann corneal dystrophy</p>
          </list-item>
          <list-item>
            <p>Schnyder corneal dystrophy</p>
          </list-item>
          <list-item>
            <p>Limbal vernal keratoconjunctivitis</p>
          </list-item>
          <list-item>
            <p>Exposure keratopathy</p>
          </list-item>
          <list-item>
            <p>Dry eye syndrome&#x000a0;<xref ref-type="bibr" rid="article-166504.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Bullous keratopathy&#x000a0;<xref ref-type="bibr" rid="article-166504.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Pertinent&#x000a0;studies and ongoing trials are crucial for developing evidence-based treatment guidelines for PHSCD, enhancing the understanding of the disease, and exploring new and effective therapeutic interventions to improve patient outcomes.</p>
        <p>
<bold>Pertinent Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Maust and Raber (2003)&#x000a0;conducted an initial comprehensive study on PHSCD, providing a foundational understanding of its clinical presentation and differentiation from similar conditions such as Salzmann nodular degeneration. The study involved detailed slit-lamp biomicroscopy and histopathological analysis, confirming the distinct peripheral subepithelial fibrosis characteristic of PHSCD. This study remains a cornerstone for diagnosing and managing PHSCD cases.<xref ref-type="bibr" rid="article-166504.r1">[1]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In a recent investigation, Raber and Eagle (2022) expanded on the clinical features and long-term outcomes of patients with PHSCD. The study included advanced imaging techniques such as AS-OCT and in vivo corneal confocal microscopy, which provided detailed insights into the structural abnormalities associated with PHSCD. This research highlighted the importance of these imaging modalities in diagnosing affected patients and monitoring the progression of their disease.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Maharana et al (2016)&#x000a0;focused on the treatment outcomes of various interventions for PHSCD. The study compared the effectiveness of superficial keratectomy and phototherapeutic keratectomy in improving visual acuity and reducing corneal opacities.<bold>&#x000a0;</bold>Both procedures were beneficial, but phototherapeutic keratectomy provided slightly better refractive outcomes.<xref ref-type="bibr" rid="article-166504.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Graue-Hern&#x000e1;ndez et al (2010)&#x000a0;explored the epidemiology and genetic factors of PHSCD, suggesting a possible hereditary component. The research included genetic analyses and family history evaluations, indicating that certain genetic markers might predispose individuals to develop PHSCD. These findings&#x000a0;may lead to more targeted and personalized treatment approaches.<xref ref-type="bibr" rid="article-166504.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ongoing Trials</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Trial on novel anti-inflammatory agents: An ongoing clinical trial is evaluating the safety and efficacy of a new class of anti-inflammatory drugs in patients with PHSCD. Preliminary results indicate a significant reduction in corneal thickness and improvement in patient-reported outcomes. This trial aims to provide new therapeutic options for managing inflammation associated with PHSCD.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prospective study of phototherapeutic keratectomy versus superficial keratectomy: This trial directly compares the long-term outcomes of phototherapeutic keratectomy and superficial keratectomy in treating those with PHSCD. Early data suggest that while both procedures are effective, phototherapeutic keratectomy may offer better refractive results. The study is expected to be completed within the next&#x000a0;2 years and could influence future surgical management guidelines for PHSCD cases.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic basis of PHSCD: Researchers are investigating the genetic underpinnings of PHSCD to understand hereditary patterns and potential genetic markers associated with the disease. This ongoing study aims to identify specific genes that may predispose individuals to PHSCD, potentially leading to more personalized treatment strategies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Impact of amniotic membrane transplantation: Another ongoing study is assessing the efficacy of amniotic membrane transplantation in promoting corneal healing and reducing symptoms in severe cases of PHSCD. Initial results are promising, showing improved epithelial healing and patient comfort. This trial could expand the therapeutic options for patients with advanced PHSCD.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Management of PHSCD involves medical and surgical interventions, each of which can be associated with specific toxicities and potential adverse events. Effective management of these adverse events is crucial for maintaining patient comfort and treatment efficacy.</p>
        <p>
<bold>Medical Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lubricating eye drops
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Preservatives in some eye drops can cause ocular surface toxicity and allergic reactions.</p></list-item><list-item><p>Management: Use preservative-free formulations to minimize adverse events. Monitor for signs of allergic reactions and switch products if necessary.<xref ref-type="bibr" rid="article-166504.r38">[38]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anti-inflammatory medications
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Long-term use of topical corticosteroids can lead to increased intraocular pressure, cataract formation, and delayed wound healing.</p></list-item><list-item><p>Management: Regularly monitor intraocular pressure and perform periodic eye examinations to detect cataracts early. Limit the duration of steroid use and use the lowest effective dose. Consider steroid-sparing agents such as nonsteroidal anti-inflammatory drugs when possible.<xref ref-type="bibr" rid="article-166504.r39">[39]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immunomodulatory agents, such as cyclosporine A and tacrolimus
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Patients may experience burning sensations, redness, and potential for secondary infections.&#x000a0;</p></list-item><list-item><p>Management: Advise patients on the possibility of initial discomfort. Monitor for signs of infection and manage promptly with appropriate antimicrobial therapy if needed.<xref ref-type="bibr" rid="article-166504.r40">[40]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertonic saline
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Stinging and discomfort may occur upon application of hypertonic saline.&#x000a0;</p></list-item><list-item><p>Management: Advise patients on the temporary nature of stinging. Suggest refrigerating the drops to reduce discomfort during application.<xref ref-type="bibr" rid="article-166504.r41">[41]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Surgical Interventions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Superficial keratectomy
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Postoperative pain, infection, delayed epithelial healing, and corneal haze may occur.&#x000a0;</p></list-item><list-item><p>Management: Provide appropriate postoperative pain management with oral analgesics and lubricating eye drops. Prescribe prophylactic antibiotics to prevent infection. Monitor for signs of delayed healing and manage with bandage contact lenses or amniotic membrane if needed.<xref ref-type="bibr" rid="article-166504.r42">[42]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Phototherapeutic keratectomy&#x000a0;
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Patients may experience postoperative discomfort, transient visual disturbances, infection, and recurrence of corneal irregularities.</p></list-item><list-item><p>Management: Offer pain relief with oral analgesics and topical anesthetics. Educate patients about the potential for transient visual changes. Prescribe prophylactic antibiotics and monitor patients closely for signs of infection. Regular follow-up is required to detect and manage any recurrence of irregularities.<xref ref-type="bibr" rid="article-166504.r43">[43]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amniotic membrane transplantation
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Risks include infection, displacement of the membrane, and delayed healing.</p></list-item><list-item><p>Management: Ensure proper surgical techniques are used to secure the membrane. Prescribe prophylactic antibiotics and schedule regular follow-ups with patients to monitor for complications.<xref ref-type="bibr" rid="article-166504.r44">[44]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Corneal transplantation
<list list-type="bullet"><list-item><p>Toxicity/adverse events: Graft rejection, infection, and postoperative astigmatism may occur.&#x000a0;</p></list-item><list-item><p>Management: Use immunosuppressive therapy to prevent graft rejection. Prescribe prophylactic antibiotics and monitor for signs of infection. If necessary, manage postoperative astigmatism with glasses, contact lenses, or additional surgical procedures.<xref ref-type="bibr" rid="article-166504.r45">[45]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>General Adverse Event Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient education: Educate patients about the potential&#x000a0;adverse events associated with treatments and the importance of adhering to prescribed regimens. Inform patients about the symptoms of complications that require prompt medical attention.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Regular monitoring: Schedule regular follow-up visits to monitor for adverse events and treatment efficacy. Use appropriate diagnostic tools such as slit-lamp examination, OCT, and intraocular pressure measurements.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multidisciplinary approach: Collaborate with other healthcare professionals, including primary care clinicians and specialists, to manage systemic conditions affecting ocular health.<xref ref-type="bibr" rid="article-166504.r46">[46]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s12" sec-type="Staging">
        <title>Staging</title>
        <p>There is no universally accepted staging system specifically for PHSCD. However, the condition can be described and monitored based on the clinical severity and extent of corneal involvement. Staging may prove helpful in a clinical setting. A proposed approach to categorize the stages of PHSCD based on the available literature and clinical observations is as follows:</p>
        <p>
<bold>Stage 1: Early PHSCD</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical features:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Mild peripheral subepithelial fibrosis</p>
              </list-item>
              <list-item>
                <p>Minimal visual disturbance or asymptomatic</p>
              </list-item>
              <list-item>
                <p>Slightly elevated nodular lesions restricted to the peripheral cornea</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnostic tools:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Slit-lamp biomicroscopy</p>
              </list-item>
              <list-item>
                <p>AS-OCT showing hyperreflective subepithelial band</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Observation or conservative treatment with lubricating eye drops and anti-inflammatory medications&#x000a0;<xref ref-type="bibr" rid="article-166504.r4">[4]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Stage 2: Moderate PHSCD</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical features:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Increased peripheral subepithelial fibrosis extending toward the mid-periphery</p>
              </list-item>
              <list-item>
                <p>Moderate visual disturbance with mild irregular astigmatism</p>
              </list-item>
              <list-item>
                <p>More pronounced nodular lesions with possible superficial neovascularization</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnostic tools:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>AS-OCT shows a more extensive hyperreflective band breaking through the Bowman layer</p>
              </list-item>
              <list-item>
                <p>In vivo confocal microscopy indicates increased fibrotic structures</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Continued use of lubricating and anti-inflammatory medications</p>
              </list-item>
              <list-item>
                <p>Consideration of surgical interventions such as superficial keratectomy or&#x000a0;phototherapeutic keratectomy <xref ref-type="bibr" rid="article-166504.r1">[1]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Stage 3: Advanced PHSCD</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical features:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Severe peripheral and mid-peripheral subepithelial fibrosis</p>
              </list-item>
              <list-item>
                <p>Significant visual impairment due to irregular astigmatism and scarring</p>
              </list-item>
              <list-item>
                <p>Extensive nodular lesions with neovascularization and possible central corneal involvement</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnostic tools:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>AS-OCT and in vivo confocal microscopy&#x000a0;show extensive fibrosis involving multiple corneal layers</p>
              </list-item>
              <list-item>
                <p>Corneal topography reveals significant irregular astigmatism</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Aggressive anti-inflammatory therapy</p>
              </list-item>
              <list-item>
                <p>Surgical interventions such as phototherapeutic keratectomy, amniotic membrane transplantation, or corneal transplantation in severe cases&#x000a0;<xref ref-type="bibr" rid="article-166504.r11">[11]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PHSCD is a slowly progressive bilateral symmetric disease. About one-third of patients&#x000a0;are asymptomatic, another one-third require conservative management with lubricating eye drops, and another one-third&#x000a0;may require surgical management with keratectomy.<xref ref-type="bibr" rid="article-166504.r13">[13]</xref><xref ref-type="bibr" rid="article-166504.r30">[30]</xref>&#x000a0;There have been a few documented cases of recurrence after surgical intervention; however, risk factors for recurrence have not yet been identified.<xref ref-type="bibr" rid="article-166504.r30">[30]</xref>&#x000a0; Repeated surgical excision can be considered in the rare event of PHSCD recurrence.</p>
        <p>The prognosis of PHSCD varies depending on the severity of the condition at diagnosis and the effectiveness of the treatment implemented. Generally, PHSCD is slowly progressive, and with appropriate management, patients can maintain good visual function and quality of life. However, the condition can lead to significant visual impairment if left untreated or complications arise.</p>
        <p>
<bold>Factors Influencing Prognosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severity at presentation: The stage at which PHSCD is diagnosed significantly impacts the prognosis. Early stages with minimal subepithelial fibrosis and no central corneal involvement generally have a better prognosis. In contrast, advanced stages with extensive fibrosis and significant visual impairment may require more aggressive interventions and have a more guarded prognosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Response to treatment: The effectiveness of medical and surgical treatments influences the outcome. Patients who respond well to topical anti-inflammatory medications and surgical interventions such as superficial keratectomy or phototherapeutic keratectomy typically have a favorable prognosis. Regular follow-ups and adherence to treatment regimens are crucial for optimal outcomes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Complications: The development of complications such as infection, corneal neovascularization, or graft rejection in cases requiring corneal transplantation can negatively impact the prognosis. Prompt identification and management of these complications are essential to improve outcomes.<xref ref-type="bibr" rid="article-166504.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Long-Term Outlook</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Visual acuity: Many patients can achieve and maintain good visual acuity with proper management. Superficial keratectomy and phototherapeutic keratectomy are particularly effective in reducing corneal opacities and improving vision.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Recurrence: Subepithelial fibrosis can recur after surgical interventions. Regular monitoring and early intervention at signs of recurrence are essential for preventing significant visual impairment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Quality of life: Effective management of PHSCD can significantly improve the patient's quality of life by alleviating symptoms such as ocular discomfort and visual disturbances. Patient education and treatment adherence play critical roles in achieving this goal.<xref ref-type="bibr" rid="article-166504.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Prognostic Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Raber and Eagle (2022) conducted a study evaluating the long-term outcomes of patients with PHSCD, showing that those who underwent early and appropriate intervention maintained good visual function over several years. The authors emphasized the importance of regular monitoring to promptly detect and manage any recurrence.<xref ref-type="bibr" rid="article-166504.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Maust and Raber (2003) provided a detailed case series highlighting the variable progression of PHSCD and the factors associated with favorable outcomes. The authors reported that early-stage disease with minimal fibrosis had a better prognosis compared to advanced cases with extensive subepithelial involvement.<xref ref-type="bibr" rid="article-166504.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>The prognosis of PHSCD depends on the stage of the disease at diagnosis, the response to treatment, and the occurrence of complications. Early detection and appropriate management are crucial for maintaining visual function and improving the quality of life. Regular follow-ups and patient adherence to treatment regimens are vital in achieving favorable outcomes.</p>
      </sec>
      <sec id="article-166504.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Understanding the potential complications of PHSCD is essential for clinicians to anticipate patient care challenges and mitigate risks associated with disease progression and treatment. Complications of PHSCD include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Visual impairment</p>
          </list-item>
          <list-item>
            <p>Blepharospasms</p>
          </list-item>
          <list-item>
            <p>Recurrent corneal erosions</p>
          </list-item>
          <list-item>
            <p>Excessive tearing&#x000a0;or irritation</p>
          </list-item>
          <list-item>
            <p>Corneal neovascularization</p>
          </list-item>
          <list-item>
            <p>Infection</p>
          </list-item>
          <list-item>
            <p>Steroid-induced glaucoma</p>
          </list-item>
          <list-item>
            <p>Steroid-induced cataracts</p>
          </list-item>
          <list-item>
            <p>Delayed wound healing</p>
          </list-item>
          <list-item>
            <p>Graft rejection</p>
          </list-item>
          <list-item>
            <p>Scarring</p>
          </list-item>
          <list-item>
            <p>Opacification</p>
          </list-item>
          <list-item>
            <p>Irregular astigmatism</p>
          </list-item>
          <list-item>
            <p>Persistent corneal edema</p>
          </list-item>
          <list-item>
            <p>Dry eye syndrome</p>
          </list-item>
          <list-item>
            <p>Corneal ulceration</p>
          </list-item>
          <list-item>
            <p>Secondary glaucoma</p>
          </list-item>
          <list-item>
            <p>Persistent epithelial defects</p>
          </list-item>
          <list-item>
            <p>Conjunctival hyperemia</p>
          </list-item>
          <list-item>
            <p>Photophobia</p>
          </list-item>
          <list-item>
            <p>Eye pain</p>
          </list-item>
          <list-item>
            <p>Foreign body sensation</p>
          </list-item>
          <list-item>
            <p>Chronic ocular surface inflammation</p>
          </list-item>
          <list-item>
            <p>Decreased contrast sensitivity</p>
          </list-item>
          <list-item>
            <p>Corneal perforation</p>
          </list-item>
          <list-item>
            <p>Epithelial ingrowth</p>
          </list-item>
          <list-item>
            <p>Anterior segment inflammation&#x000a0;<xref ref-type="bibr" rid="article-166504.r2">[2]</xref><xref ref-type="bibr" rid="article-166504.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Effective postoperative and rehabilitation care is essential for patients with PHSCD who have undergone surgical interventions such as superficial keratectomy, phototherapeutic keratectomy, or corneal transplantation. This care promotes healing, prevents complications, and restores visual function.</p>
        <p>
<bold>Immediate Postoperative Care</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Medications
<list list-type="bullet"><list-item><p>Antibiotics: Topical antibiotics to prevent infection</p></list-item><list-item><p>Anti-inflammatory agents: Corticosteroids or nonsteroidal anti-inflammatory drugs to reduce inflammation and prevent scarring</p></list-item><list-item><p>Lubricants: Preservative-free artificial tears to maintain ocular surface hydration&#x000a0;<xref ref-type="bibr" rid="article-166504.r48">[48]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Protective measures
<list list-type="bullet"><list-item><p>Bandage contact lenses: To protect the corneal surface and promote epithelial healing</p></list-item><list-item><p>Eye shield: To protect the eye from trauma, especially during sleep&#x000a0;<xref ref-type="bibr" rid="article-166504.r49">[49]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Follow-Up Care</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Regular monitoring
<list list-type="bullet"><list-item><p>Slit-lamp examination: Frequent examinations to monitor the healing process and detect early signs of complications</p></list-item><list-item><p>Intraocular pressure monitoring: Regular checks if corticosteroids are used to prevent steroid-induced glaucoma&#x000a0;<xref ref-type="bibr" rid="article-166504.r28">[28]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnostic imaging
<list list-type="bullet"><list-item><p>AS-OCT: To assess the integrity of the corneal layers and detect any recurrence of subepithelial fibrosis</p></list-item><list-item><p>Corneal topography: To monitor changes in corneal shape and detect irregular astigmatism</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Long-Term Rehabilitation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Vision correction
<list list-type="bullet"><list-item><p>Spectacles or contact lenses: To correct residual refractive errors and improve visual acuity</p></list-item><list-item><p>Rigid gas permeable lenses: For patients with significant irregular astigmatism&#x000a0;<xref ref-type="bibr" rid="article-166504.r14">[14]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rehabilitation therapy
<list list-type="bullet"><list-item><p>Visual rehabilitation: Includes exercises and strategies to optimize the use of remaining vision</p></list-item><list-item><p>Occupational therapy: To help patients adapt to any permanent visual changes and maintain their daily activities&#x000a0;<xref ref-type="bibr" rid="article-166504.r50">[50]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient education
<list list-type="bullet"><list-item><p>Adherence to medications: Emphasize the importance of following the prescribed medication regimen to prevent complications</p></list-item><list-item><p>Symptom awareness: Educate patients on the signs of complications, such as infection, increased IOP, or recurrence of fibrosis, and the need for prompt medical attention</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Lifestyle and Environmental Adjustments</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sun protection
<list list-type="bullet"><list-item><p>Sunglasses: To protect against ultraviolet radiation and reduce discomfort from light sensitivity&#x000a0;<xref ref-type="bibr" rid="article-166504.r2">[2]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Hydration
<list list-type="bullet"><list-item><p>Humidifiers: Use in the home to maintain a moist environment, reducing dry eye symptoms</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoiding eye irritants
<list list-type="bullet"><list-item><p>Environmental control: Minimize exposure to dust, smoke, and other irritants that can exacerbate symptoms&#x000a0;<xref ref-type="bibr" rid="article-166504.r15">[15]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Psychological Support</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Counseling
<list list-type="bullet"><list-item><p>Support groups: Connecting with others who have similar conditions can provide emotional support and practical advice</p></list-item><list-item><p>Professional counseling: For patients struggling with the psychological impact of chronic eye disease and visual impairment</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Postoperative and rehabilitation care for patients with PHSCD involves medication management, protective measures, regular monitoring, and long-term vision rehabilitation. Patient education and lifestyle adjustments are crucial in preventing complications and promoting optimal recovery and quality of life. Regular follow-ups with an ophthalmologist ensure timely detection and management of any issues that may arise during the postoperative period.<xref ref-type="bibr" rid="article-166504.r6">[6]</xref></p>
      </sec>
      <sec id="article-166504.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Treating patients with PHSCD requires a multidisciplinary approach involving various specialists. Key consultations that may be necessary for comprehensive management are as follows:</p>
        <p>
<bold>Ophthalmology Subspecialists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cornea specialist
<list list-type="bullet"><list-item><p>Role: Primary management of PHSCD, including diagnosis, medical treatment, and surgical interventions</p></list-item><list-item><p>Importance: Expertise in corneal diseases ensures accurate diagnosis and effective treatment planning&#x000a0;<xref ref-type="bibr" rid="article-166504.r51">[51]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oculoplastic surgeon
<list list-type="bullet"><list-item><p>Role: Consultation for surgical interventions for associated eyelid abnormalities or complex reconstructive procedures</p></list-item><list-item><p>Importance: Ensures optimal surgical outcomes and addresses any structural issues affecting corneal health</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glaucoma specialist
<list list-type="bullet"><list-item><p>Role: Monitoring and managing intraocular pressure, especially if corticosteroids are used</p></list-item><list-item><p>Importance: Prevents steroid-induced glaucoma and manages any preexisting or secondary glaucoma</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Other Relevant Specialists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatologist
<list list-type="bullet"><list-item><p>Role: Consultation if PHSCD is associated with systemic autoimmune conditions</p></list-item><list-item><p>Importance: Coordinates systemic immunosuppressive therapy and monitors for systemic manifestations</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infectious disease specialist
<list list-type="bullet"><list-item><p>Role: Management of any infectious complications, especially in immunocompromised patients</p></list-item><list-item><p>Importance: Provides expertise in selecting appropriate antimicrobial therapies</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Occupational therapist
<list list-type="bullet"><list-item><p>Role: Rehabilitation and adaptation strategies for patients with significant visual impairment</p></list-item><list-item><p>Importance: Helps patients maintain independence and improve their quality of life</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic counselor
<list list-type="bullet"><list-item><p>Role: Evaluation if there is a suspected hereditary component to PHSCD</p></list-item><list-item><p>Importance: Provides genetic testing and counseling to inform management and family planning</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Multidisciplinary Team&#x000a0;Members</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary care clinician
<list list-type="bullet"><list-item><p>Role: Overall health management, care coordination, and addressing any systemic health issues</p></list-item><list-item><p>Importance: Ensures holistic care and monitors systemic conditions that may impact ocular health&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Optometrist
<list list-type="bullet"><list-item><p>Role: Regular vision assessments and fitting of corrective lenses</p></list-item><list-item><p>Importance: Helps manage refractive errors and ensure optimal visual function</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Patient Education and Support</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient support groups
<list list-type="bullet"><list-item><p>Role: Provide emotional support, share experiences, and offer practical advice</p></list-item><list-item><p>Importance: Enhances patient coping mechanisms and provides a sense of community</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychologist&#x000a0;or counselor
<list list-type="bullet"><list-item><p>Role: Address the psychological impact of chronic eye disease and visual impairment</p></list-item><list-item><p>Importance: Supports mental health and helps patients manage the emotional aspects of PHSCD</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Consultations with various specialists are essential for comprehensively treating patients with PHSCD. These consultations address all aspects of the disease, including ocular health, systemic conditions, and patient well-being. Collaboration among these specialists facilitates a holistic approach to care, optimizing outcomes for individuals with PHSCD.</p>
      </sec>
      <sec id="article-166504.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Effective deterrence and patient education are crucial in managing PHSCD. This proactive approach fosters patient engagement and enhances overall management strategies.</p>
        <p>
<bold>Deterrence Strategies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Routine eye examinations: Patients are encouraged to maintain&#x000a0;routine&#x000a0;eye examinations with their ophthalmologist or optometrist for prompt diagnosis of PHSCD.</p>
          </list-item>
          <list-item>
            <p>Mitigating risk factors: Patients with PHSCD should avoid extended contact lens wear and alleviate dry eye symptoms if present.</p>
          </list-item>
          <list-item>
            <p>Maintaining adequate ocular surface health: Patients should&#x000a0;manage&#x000a0;ocular irritation and dry eye with lubrication drops.<xref ref-type="bibr" rid="article-166504.r52">[52]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Patient Education</bold>
</p>
        <p>Patients with risk factors such as contact lens use, ocular surface disease, and prior ocular&#x000a0;surgery must be educated regarding the risk of PHSCD. Once the diagnosis is made, patients should be advised to maintain their ocular surface health with adequate lubrication and avoid using contact lenses. Patients should also be&#x000a0;aware that PHSCD is a slow-progressing bilateral disease that may affect their visual acuity. If PHSCD starts to affect the visual axis,&#x000a0;individuals must be educated that surgical management with keratectomy is the only option to restore their visual acuity. Patients should be advised that there is a slight chance of recurrence after surgery, so a second surgery&#x000a0;could be needed to address the issue. Patients should also be educated to attend routine follow-up appointments to monitor disease progression.<xref ref-type="bibr" rid="article-166504.r53">[53]</xref></p>
      </sec>
      <sec id="article-166504.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>By highlighting key clinical tips, common challenges in diagnosis and management, and effective prevention measures, clinicians can refine their approach to PHSCD, ensuring optimal patient care and minimizing potential complications.</p>
        <p>
<bold>Pearls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early diagnosis: Early recognition and diagnosis of PHSCD can significantly improve management outcomes. Regular eye examinations and advanced imaging techniques such as AS-OCT and IVCM are crucial for detecting early signs of the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tailored treatment plans: Individualized treatment plans that consider the severity of the disease and patient-specific factors are essential. Combining medical and surgical treatments can optimize visual outcomes and patient comfort.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Interdisciplinary approach: Collaboration between ophthalmologists, cornea specialists, and other healthcare professionals ensures comprehensive care. This interdisciplinary approach can address both ocular and systemic aspects of the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient education: Educating patients about the nature of PHSCD, potential complications, and the importance of adherence to treatment regimens is critical. Informed patients are more likely to comply with treatment and recognize early signs of complications.<xref ref-type="bibr" rid="article-166504.r54">[54]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Disposition</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Regular follow-up: Patients with PHSCD require regular follow-up visits to monitor disease progression, assess treatment efficacy, and adjust management plans as needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Long-term management: PHSCD is a chronic condition that may require long-term management. Continuous monitoring and periodic adjustments to the treatment plan can help maintain visual function and prevent complications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Referral to specialists: Timely referral to cornea specialists and other relevant healthcare professionals can ensure that patients receive the best care. Specialized interventions and advanced treatments can significantly improve outcomes.<xref ref-type="bibr" rid="article-166504.r55">[55]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pitfalls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Misdiagnosis: PHSCD can be mistaken for other corneal diseases, such as Salzmann nodular degeneration, band keratopathy, or Terrien marginal degeneration. Accurate diagnosis using advanced imaging techniques is essential to avoid mismanagement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Overuse of steroids: Long-term use of topical corticosteroids can lead to complications such as elevated intraocular pressure, cataracts, and delayed wound healing. Monitoring and using steroid-sparing agents when possible can mitigate these risks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inadequate follow-up: Infrequent follow-up visits can lead to missed complications or disease progression. Regular monitoring and patient education about the importance of follow-up are vital.<xref ref-type="bibr" rid="article-166504.r56">[56]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Prevention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Control of risk factors: Managing underlying systemic conditions, such as autoimmune diseases, can help prevent the worsening of PHSCD. Regular check-ups and appropriate systemic treatments are essential.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Protective measures: Patients should be advised to protect their eyes from environmental irritants,&#x000a0;ultraviolet&#x000a0;radiation, and trauma. Using sunglasses and avoiding exposure to dust and smoke can help maintain ocular surface health.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Early intervention: Prompt treatment of early signs and symptoms can prevent the progression of PHSCD. Early intervention with medical or surgical treatments can improve long-term outcomes.<xref ref-type="bibr" rid="article-166504.r57">[57]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Additional Information</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Research and advances: Ongoing research into the pathophysiology, genetic basis, and novel treatments for PHSCD is essential. Participation in clinical trials and registries can provide valuable data and improve understanding of the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Support networks: Connecting patients with support groups and counseling services can provide emotional support and practical advice for managing chronic eye conditions. Peer support can enhance coping strategies and improve the equality of life.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technological integration: Using advanced diagnostic and treatment technologies can enhance the precision of care. Innovations in imaging, surgical techniques, and pharmacotherapy can improve outcomes for patients with PHSCD.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing PHSCD cases is most effectively accomplished through an interprofessional team approach. Individuals experiencing vision issues,&#x000a0;ocular irritation,&#x000a0;and significant astigmatism warrant special attention through referral to an optician, ophthalmic nurse, and ophthalmologist. A straightforward slit-lamp examination and topography can definitively confirm the diagnosis. Conservative and surgical treatment options for patients with PHSCD are currently available. Timely identification and suitable visual rehabilitation efforts can significantly enhance the quality of life for affected individuals.&#x000a0;Patient education is critical, particularly regarding risk factors such as contact lens use, ocular surface disease, and prior ocular surgeries, which are linked to disease progression.</p>
        <p>By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance.<xref ref-type="bibr" rid="article-166504.r58">[58]</xref>&#x000a0;Effective management of PHSCD cases requires a coordinated, multidisciplinary approach involving various healthcare professionals. This collaboration ensures comprehensive, patient-centered care that enhances outcomes, patient safety, and team performance.</p>
        <p>
<bold>Skills and Strategies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Interprofessional communication</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Importance: Clear and open communication among team members is crucial for coordinating care and addressing all aspects of the patient's condition.</p>
              </list-item>
              <list-item>
                <p>Strategy: Conduct regular team meetings and use shared electronic health records to update all members on the patient's status and treatment plan.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient-centered care</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Importance: Involving patients in decision-making and providing personalized care plans improves adherence and satisfaction.</p>
              </list-item>
              <list-item>
                <p>Strategy: Educate patients about PHSCD, discuss treatment options, and consider their preferences and lifestyle when designing care plans.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ethics and responsibilities</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Importance: Maintaining high ethical standards ensures trust and respect in the patient-clinician relationship.</p>
              </list-item>
              <list-item>
                <p>Strategy: Adhere to professional codes of conduct, ensure informed consent, and respect patient confidentiality.<xref ref-type="bibr" rid="article-166504.r59">[59]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Roles and Responsibilities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physicians (ophthalmologists and cornea specialists)</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Role: Diagnose PHSCD, develop and implement treatment plans, perform surgical interventions, and monitor disease progression.</p>
              </list-item>
              <list-item>
                <p>Responsibilities: Lead the healthcare team, coordinate with other specialists, and provide follow-up care.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Advanced practitioners (nurse practitioners and physician assistants)</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Role: Assist in managing PHSCD cases by conducting initial assessments, providing patient education, and managing routine follow-ups.</p>
              </list-item>
              <list-item>
                <p>Responsibilities: Ensure continuity of care, support the clinician's treatment plan, and address patient concerns promptly.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nurses</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Role: Provide direct patient care, assist with procedures, administer medications, and offer emotional support.</p>
              </list-item>
              <list-item>
                <p>Responsibilities: Monitor patient progress, educate patients about self-care and treatment adherence, and report any changes in condition to the healthcare team.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pharmacists</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Role: Manage medication therapy, ensure appropriate use of prescribed drugs, and counsel patients on medication adherence.</p>
              </list-item>
              <list-item>
                <p>Responsibilities: Review medication regimens for potential interactions, educate patients on&#x000a0;adverse effects, and collaborate with the healthcare team to optimize pharmacotherapy.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Occupational therapists</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Role: Assist patients with visual impairments in adapting to daily activities and maintaining independence.</p>
              </list-item>
              <list-item>
                <p>Responsibilities: Develop personalized rehabilitation plans, provide adaptive tools and strategies, and offer emotional and practical support.<xref ref-type="bibr" rid="article-166504.r60">[60]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Care Coordination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multidisciplinary meetings</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Schedule regular meetings to discuss patient cases, treatment progress, and any challenges encountered, ensuring that all team members are informed and can contribute their expertise.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Electronic health records&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Using electronic health records to share patient information among team members ensures everyone can access the latest data and coordinate care effectively.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient education programs</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Implementing comprehensive education programs that inform patients about PHSCD, treatment options, and self-care practices enhances patient engagement and adherence to treatment plans.<xref ref-type="bibr" rid="article-166504.r61">[61]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Enhancing Patient Safety and Outcomes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Standardized protocols
<list list-type="bullet"><list-item><p>Developing and adhering to standardized treatment protocols and guidelines ensures consistency and quality of care.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Continuous education and training
<list list-type="bullet"><list-item><p>Providing ongoing education and training helps healthcare professionals stay updated on the latest advancements in PHSCD&#x000a0;case management.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Quality improvement initiatives
<list list-type="bullet"><list-item><p>Implementing quality improvement initiatives that regularly assess and enhance care processes, patient safety, and treatment outcomes.<xref ref-type="bibr" rid="article-166504.r62">[62]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-166504.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=166504&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=166504">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/166504/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=166504">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-166504.s21">
        <fig id="article-166504.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Schirmer Test Results. This image shows&#x000a0;a patient's Schirmer test results. The right eye has extremely&#x000a0;low tear production at 3 mm, indicating severe dry eye disease. The left eye has&#x000a0;a normal test result at 20 mm. Contributed by Marco Zeppieri, MD, PhD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Schirmer__Test__results" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-166504.s22">
        <title>References</title>
        <ref id="article-166504.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maust</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Raber</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration.</article-title>
            <source>Eye Contact Lens</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>266</fpage>
            <page-range>266-9</page-range>
            <pub-id pub-id-type="pmid">14555908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raber</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Hypertrophic Subepithelial Corneal Degeneration.</article-title>
            <source>Cornea</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-191</page-range>
            <pub-id pub-id-type="pmid">34620763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunzinger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Voulgari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Petrovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashemi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kymionis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration: clinical aspects related to in vivo confocal microscopy and optical coherence tomography.</article-title>
            <source>Int Med Case Rep J</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>237</fpage>
            <page-range>237-241</page-range>
            <pub-id pub-id-type="pmid">31440105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000e4;rventausta</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tervo</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Kivel&#x000e4;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holopainen</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration - clinical and histopathological features.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>8</issue>
            <fpage>774</fpage>
            <page-range>774-82</page-range>
            <pub-id pub-id-type="pmid">24655442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auteri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Presa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration versus Salzmann's nodular degeneration: A clinical and surgical comparison.</article-title>
            <source>Ocul Surf</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>23</volume>
            <fpage>71</fpage>
            <page-range>71-73</page-range>
            <pub-id pub-id-type="pmid">34838722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>LaHood</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Hypertrophic Subepithelial Corneal Degeneration on a Laser-Assisted In Situ Keratomileusis Flap.</article-title>
            <source>Eye Contact Lens</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-53</page-range>
            <pub-id pub-id-type="pmid">34310351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schargus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kusserow</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hofmann-Rummelt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schlunck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geerling</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration presenting with bilateral nasal and temporal corneal changes.</article-title>
            <source>Eye (Lond)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-97</page-range>
            <pub-id pub-id-type="pmid">25277306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridhar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Anatomy of cornea and ocular surface.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-194</page-range>
            <pub-id pub-id-type="pmid">29380756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meek</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Knupp</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Corneal structure and transparency.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>49</volume>
            <fpage>1</fpage>
            <page-range>1-16</page-range>
            <pub-id pub-id-type="pmid">26145225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rommel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grisanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ranjbar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Hypertrophic Subepithelial Corneal Degeneration.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>08</day>
            <volume>135</volume>
            <issue>6</issue>
            <fpage>e170664</fpage>
            <pub-id pub-id-type="pmid">28594994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeng</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Millstein</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Reduction of hyperopia and astigmatism after superficial keratectomy of peripheral hypertrophic subepithelial corneal degeneration.</article-title>
            <source>Eye Contact Lens</source>
            <year>2006</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>153</fpage>
            <page-range>153-6</page-range>
            <pub-id pub-id-type="pmid">16702871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stokkermans</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <chapter-title>Meibomian Gland Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">35593799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000e4;rventausta</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Holopainen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zalentein</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Paakkanen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wennerstr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sepp&#x000e4;nen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lokki</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tervo</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration: characterization, treatment and association with human leucocyte antigen genes.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-6</page-range>
            <pub-id pub-id-type="pmid">23388055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Misirkhanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Musayeva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasielica-Poslednik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for peripheral hypertrophic subepithelial corneal opacification.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-448</page-range>
            <pub-id pub-id-type="pmid">36464930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wasielica-Poslednik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weyer-Elberich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vossmerbaeumer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lisch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Visualization of corneal vascularization in peripheral hypertrophic subepithelial corneal opacification with OCT angiography.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>8</issue>
            <fpage>e974</fpage>
            <page-range>e974-e978</page-range>
            <pub-id pub-id-type="pmid">29671946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Intricate insights into immune response in dry eye disease.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>1248</fpage>
            <page-range>1248-1255</page-range>
            <pub-id pub-id-type="pmid">37026255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venugopal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ravindran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uduman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Management of symblepharon with Gore-tex as a novel treatment option for ocular chemical burns.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>05</day>
            <fpage>11206721241238302</fpage>
            <pub-id pub-id-type="pmid">38444229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gubert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Retrospective multifactorial analysis of <italic>Pythium keratitis</italic> and review of literature.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1095</fpage>
            <page-range>1095-1101</page-range>
            <pub-id pub-id-type="pmid">33913840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Okoye</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Traumatic Cataract</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">37603642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Contact Lens&#x02013;Related Complications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">36512659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maharana</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vajpayee</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Salzmann's Nodular Degeneration.</article-title>
            <source>Ocul Surf</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-30</page-range>
            <pub-id pub-id-type="pmid">26462409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Salzmann's nodular degeneration.</article-title>
            <source>Exp Eye Res</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>202</volume>
            <fpage>108351</fpage>
            <pub-id pub-id-type="pmid">33212141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chihaia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hringer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eberwein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reinhard</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Re: peripheral hypertrophic subepithelial corneal degeneration - clinical and histopathological features.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>e593</fpage>
            <pub-id pub-id-type="pmid">25809296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Corneal stromal wound healing: Major regulators and therapeutic targets.</article-title>
            <source>Ocul Surf</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>19</volume>
            <fpage>290</fpage>
            <page-range>290-306</page-range>
            <pub-id pub-id-type="pmid">33127599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torricelli</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Santhanam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The corneal fibrosis response to epithelial-stromal injury.</article-title>
            <source>Exp Eye Res</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>142</volume>
            <fpage>110</fpage>
            <page-range>110-8</page-range>
            <pub-id pub-id-type="pmid">26675407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonde</surname>
                <given-names>JPE</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Smid</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Flachs</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Elklit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mors</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-131</page-range>
            <pub-id pub-id-type="pmid">34523121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wr&#x000f3;bel-Dudzi&#x00144;ska</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Osial</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>St&#x00119;pie&#x00144;</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Gorecka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x0017b;arnowski</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Dry Eye Symptoms and Associated Risk Factors among University Students in Poland.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2023</year>
            <month>Jan</month>
            <day>11</day>
            <volume>20</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36674068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Misirkhanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasielica-Poslednik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Schmidtmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beutel</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal opacification - Role of tear secretion, medication and systemic diseases.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>e956</fpage>
            <page-range>e956-e960</page-range>
            <pub-id pub-id-type="pmid">38536709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almulhim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magliyah</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Alfawaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Al-Muammar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alkatan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Successful surgical management of post-penetrating or deep lamellar keratoplasty Acquired Corneal Sub-Epithelial Hypertrophy (ACSH): A case series.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2020</year>
            <volume>67</volume>
            <fpage>191</fpage>
            <page-range>191-195</page-range>
            <pub-id pub-id-type="pmid">32062505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Iovieno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meligonis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Peripheral hypertrophic subepithelial corneal degeneration: nomenclature, phenotypes, and long-term outcomes.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>May</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>892</fpage>
            <page-range>892-8</page-range>
            <pub-id pub-id-type="pmid">23474249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahraki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feizi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pterygium: an update on pathophysiology, clinical features, and management.</article-title>
            <source>Ther Adv Ophthalmol</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>13</volume>
            <fpage>25158414211020152</fpage>
            <pub-id pub-id-type="pmid">34104871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Toyos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karpecki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schiffbauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>1333</fpage>
            <page-range>1333-1369</page-range>
            <pub-id pub-id-type="pmid">35608780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ouerdane</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zaazouee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>MEA</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghoneim</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gbreel</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ragab</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Nourelden</surname>
                <given-names>AZ</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C application after photorefractive keratectomy in high, moderate, or low myopia: Systematic review and meta-analysis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>3421</fpage>
            <page-range>3421-3431</page-range>
            <pub-id pub-id-type="pmid">34826969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Subconjunctival dexamethasone-assisted conjunctival autograft harvesting versus normal saline during pterygium surgery - A randomized clinical trial.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2024</year>
            <month>Feb</month>
            <day>01</day>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-222</page-range>
            <pub-id pub-id-type="pmid">38099381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Molecular and epigenetic mechanisms governing ocular surface squamous neoplasia: opportunities for diagnostics.</article-title>
            <source>Expert Rev Mol Diagn</source>
            <year>2023</year>
            <month>Dec</month>
            <day>22</day>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">38131180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Pseudophakic Bullous Keratopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">34662019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graue-Hern&#x000e1;ndez</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Mannis</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Eliasieh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greasby</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Beckett</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Salzmann nodular degeneration.</article-title>
            <source>Cornea</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-9</page-range>
            <pub-id pub-id-type="pmid">20098304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Vadoothker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Munir</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Saeedi</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Ocular Surface Disease and Glaucoma Medications: A Clinical Approach.</article-title>
            <source>Eye Contact Lens</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-18</page-range>
            <pub-id pub-id-type="pmid">30199425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peponis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kyttaris</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Chalkiadakis</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bonovas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sitaras</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.</article-title>
            <source>Lupus</source>
            <year>2010</year>
            <month>May</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>675</fpage>
            <page-range>675-82</page-range>
            <pub-id pub-id-type="pmid">20144965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinaik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barayan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shahrokhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeschke</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Management and prevention of drug resistant infections in burn patients.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>607</fpage>
            <page-range>607-619</page-range>
            <pub-id pub-id-type="pmid">31353976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2020</year>
            <month>Aug</month>
            <day>28</day>
            <volume>99</volume>
            <issue>35</issue>
            <fpage>e21655</fpage>
            <pub-id pub-id-type="pmid">32871879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moshirfar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Theis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Stoakes</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hoopes</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Management of Corneal Haze After Photorefractive Keratectomy.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>2841</fpage>
            <page-range>2841-2862</page-range>
            <pub-id pub-id-type="pmid">37603162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rathi</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sangwan</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Phototherapeutic keratectomy.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-14</page-range>
            <pub-id pub-id-type="pmid">22218239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramuta</surname>
                <given-names>T&#x0017d;</given-names>
              </name>
              <name>
                <surname>Star&#x0010d;i&#x0010d; Erjavec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kreft</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Amniotic Membrane Preparation Crucially Affects Its Broad-Spectrum Activity Against Uropathogenic Bacteria.</article-title>
            <source>Front Microbiol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>469</fpage>
            <pub-id pub-id-type="pmid">32265889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Czyz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <chapter-title>Corneal Graft Rejection</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">30085585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimmy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patient medication adherence: measures in daily practice.</article-title>
            <source>Oman Med J</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-9</page-range>
            <pub-id pub-id-type="pmid">22043406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Recurrent corneal erosion: a comprehensive review.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>325</fpage>
            <page-range>325-335</page-range>
            <pub-id pub-id-type="pmid">30809089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r48">
          <label>48</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Bacterial Keratitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">34662023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Performance of Bandage Contact Lens in Patients Post-ocular Surgeries: A Systematic Literature Review.</article-title>
            <source>Eye Contact Lens</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>49</volume>
            <issue>11</issue>
            <fpage>449</fpage>
            <page-range>449-458</page-range>
            <pub-id pub-id-type="pmid">37816246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Rajhi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Helmi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Alkatan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al-Obailan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Rajhi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Corneal Opacification with Associated Thickened Epithelium by Simple Peeling: Acquired Corneal Subepithelial Hypertrophy (ACSH).</article-title>
            <source>Saudi J Ophthalmol</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-208</page-range>
            <pub-id pub-id-type="pmid">31686959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lalgudi</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jhanji</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gurav</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Role of artificial intelligence, machine learning and deep learning models in corneal disorders&#x000a0;-&#x000a0;A narrative review.</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>104242</fpage>
            <pub-id pub-id-type="pmid">39013268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Cotch</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Janiszewski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Factors that influence the receipt of eye care.</article-title>
            <source>Am J Health Behav</source>
            <year>2008</year>
            <season>Sep-Oct</season>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>547</fpage>
            <page-range>547-56</page-range>
            <pub-id pub-id-type="pmid">18241139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsatsos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Athanasiadis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Contact Lens Use Advice-Risks and Outcomes: Are Patients Drowning in Information but Starved for Knowledge?</article-title>
            <source>Turk J Ophthalmol</source>
            <year>2023</year>
            <month>Jun</month>
            <day>21</day>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-141</page-range>
            <pub-id pub-id-type="pmid">37345286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Katalinic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalloniatis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An evidence-based approach to the routine use of optical coherence tomography.</article-title>
            <source>Clin Exp Optom</source>
            <year>2019</year>
            <month>May</month>
            <volume>102</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-259</page-range>
            <pub-id pub-id-type="pmid">30560558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Follow-up management service and health outcomes of hypertensive patients in China: A cross-sectional analysis from the national health service survey in Jiangsu province.</article-title>
            <source>Front Public Health</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>956711</fpage>
            <pub-id pub-id-type="pmid">35958831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Seitz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Salzmann's nodular degeneration of the cornea: a review and case series.</article-title>
            <source>Cornea</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>772</fpage>
            <page-range>772-7</page-range>
            <pub-id pub-id-type="pmid">16160490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandrashekara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>665</fpage>
            <page-range>665-71</page-range>
            <pub-id pub-id-type="pmid">23248391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadavand</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Heidary</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heidary</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gharebaghi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Role of ophthalmic nurses in prevention of ophthalmic diseases.</article-title>
            <source>Med Hypothesis Discov Innov Ophthalmol</source>
            <year>2013</year>
            <season>Winter</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>92</fpage>
            <page-range>92-5</page-range>
            <pub-id pub-id-type="pmid">24822227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheehan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laver</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhopti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Usherwood</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clemson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lannin</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Methods and Effectiveness of Communication Between Hospital Allied Health and Primary Care Practitioners: A Systematic Narrative Review.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>493</fpage>
            <page-range>493-511</page-range>
            <pub-id pub-id-type="pmid">33654406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rampat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deshmukh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>DSW</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dua</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>DSJ</given-names>
              </name>
            </person-group>
            <article-title>Artificial Intelligence in Cornea, Refractive Surgery, and Cataract: Basic Principles, Clinical Applications, and Future Directions.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-281</page-range>
            <pub-id pub-id-type="pmid">34224467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harrod</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Krein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saint</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Electronic health records, communication, and data sharing: challenges and opportunities for improving the diagnostic process.</article-title>
            <source>Diagnosis (Berl)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>27</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-248</page-range>
            <pub-id pub-id-type="pmid">30485175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-166504.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistri</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Badge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Enhancing Patient Safety Culture in Hospitals.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e51159</fpage>
            <pub-id pub-id-type="pmid">38283419</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
